Abstract
Background: Gaucher disease (GD) is a hereditary lysosomal storage disorder characterized by the accumulation of glucosylceramide, mainly in the cells of the reticuloendothelial system, due to a deficiency of the enzyme acid β-glucosidase (GBA). Diagnosis is usually based on measurement of GBA activity in peripheral leukocytes. The purpose of this study was to evaluate the ability of screening for GBA and chitotriosidase activity using dried blood spots on filter paper (DBS-FP) to identify individuals at high risk for GD in high-risk populations such as that of Tabuleiro do Norte, a small town in Northeastern Brazil.
Methods: Between 1 June 2007 and 31 May 2008, 740 consented residents and descendants of traditional families from Tabuleiro do Norte were submitted to screening with DBS-FP. Subjects with GBA activity < 2.19 nmol/h/mL were referred to the analysis of GBA and chitotriosidase activity in peripheral leukocytes and in plasma, respectively. Subjects at highest risk for GD (GBA activity in peripheral leukocytes < 5.6 nmol/h/mg protein) were referred to molecular analysis to confirm diagnosis.
Results: Screening with DBS-FP identified 135 subjects (18.2%) with GBA activity < 2.19 nmol/h/mL, 131 of whom remained in the study. In ten of these (7.6%), GBA activity in leukocytes was 2.6–5.5 nmol/h/mg protein. Subsequent molecular analysis confirmed six cases of heterozygosity and four normals for GD.
Conclusion: DBS-FP assay was shown to be an effective initial GD-screening strategy for high-prevalence populations in developing regions. Diagnosis could not be established from GBA activity in leukocytes alone, but required confirmation with molecular analysis.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsReferences
Abrahamov A, Elstein D et al (1995) Gaucher's disease variant characterised by progressive calcification of heart valves and unique genotype. Lancet 346(8981):1000–1003
Aerts JM, Hollak C et al (2003) Biochemistry of glycosphingolipid storage disorders: implications for therapeutic intervention. Philos Trans R Soc Lond B Biol Sci 358(1433):905–914
Amaral O, Pinto E, Fortuna M, Lacerda L (1996) Sa Miranda MC. Type 1 Gaucher disease: identification of N396T and prevalence of glucocerebrosidase mutations in the Portuguese. Hum Mutat 8:280–281
Amaral O, Marcao A et al (2000) Gaucher disease: expression and characterization of mild and severe acid beta-glucosidase mutations in Portuguese type 1 patients. Eur J Hum Genet 8(2):95–102
Beutler E, Grabowski G (2001) Gaucher disease. In: Scriver C, Beaudet A, Sly W, Valle D (eds) The metabolic and molecular bases of inheredited disease. McGraw-Hill, New York, pp 3635–3668
Beutler E, Saven A (1990) Misuse of marrow examination in the diagnosis of Gaucher disease. Blood 76(3):646–648
Brady RO, Kanfer JN et al (1966) Demonstration of a deficiency of glucocerebroside-cleaving enzyme in Gaucher's disease. J Clin Invest 45(7):1112–1115
Cabrera-Salazar MA, O'Rourke E et al (2004) Correlation of surrogate markers of Gaucher disease. Implications for long-term follow up of enzyme replacement therapy. Clin Chim Acta 344(1–2):101–107
Chamoles NA, Blanco M et al (2002) Gaucher and Niemann-Pick diseases–enzymatic diagnosis in dried blood spots on filter paper: retrospective diagnoses in newborn-screening cards. Clin Chim Acta 317(1–2):191–197
Charrow J, Esplin JA et al (1998) Gaucher disease: recommendations on diagnosis, evaluation, and monitoring. Arch Intern Med 158(16):1754–1760
Charrow J, Andersson HC et al (2000) The Gaucher registry: demographics and disease characteristics of 1698 patients with Gaucher disease. Arch Intern Med 160(18):2835–2843
Civallero G, Michelin K et al (2006) Twelve different enzyme assays on dried-blood filter paper samples for detection of patients with selected inherited lysosomal storage diseases. Clin Chim Acta 372(1–2):98–102
Damiano AM, Pastores GM et al (1998) The health-related quality of life of adults with Gaucher's disease receiving enzyme replacement therapy: results from a retrospective study. Qual Life Res 7(5):373–386
Devost NC, Choy FY (2000) Mutation analysis of Gaucher disease using dot-blood samples on FTA filter paper. Am J Med Genet 94(5):417–420
Evans MI, Galen RS et al (2005) Principles of screening. Semin Perinatol 29(6):364–366
Gelb MH, Turecek F et al (2006) Direct multiplex assay of enzymes in dried blood spots by tandem mass spectrometry for the newborn screening of lysosomal storage disorders. J Inherit Metab Dis 29(2–3):397–404
Giraldo P, Solano V et al (2005) Quality of life related to type 1 Gaucher disease: Spanish experience. Qual Life Res 14(2):453–462
Grabowski GA (2004) Gaucher disease: lessons from a decade of therapy. J Pediatr 144(5 Suppl):S15–S19
Hollak CE, van Weely S et al (1994) Marked elevation of plasma chitotriosidase activity. A novel hallmark of Gaucher disease. J Clin Invest 93(3):1288–1292
ICGG Gaucher Registry (2009) Relatório do Brasil: Brasil comparado ao resto do mundo. Relatório Anual de 2009
Kaplan P, Andersson HC et al (2006) The clinical and demographic characteristics of nonneuronopathic Gaucher disease in 887 children at diagnosis. Arch Pediatr Adolesc Med 160(6):603–608
Kishnani PS, DiRocco M et al (2009) A randomized trial comparing the efficacy and safety of imiglucerase (Cerezyme) infusions every 4 weeks versus every 2 weeks in the maintenance therapy of adult patients with Gaucher disease type 1. Mol Genet Metab 96(4):164–170
Li Y, Scott CR et al (2004) Direct multiplex assay of lysosomal enzymes in dried blood spots for newborn screening. Clin Chem 50(10):1785–1796
Masek BJ, Sims KB et al (1999) Quality of life assessment in adults with type 1 Gaucher disease. Qual Life Res 8(3):263–268
Meikle PJ, Ranieri E et al (2004) Newborn screening for lysosomal storage disorders: clinical evaluation of a two-tier strategy. Pediatrics 114(4):909–916
Mistry P, Germain DP (2007) Therapeutic objectives in Gaucher disease. Rev Méd Interne 28(Suppl 2):S171–S175
Mistry PK, Smith SJ et al (1992) Genetic diagnosis of Gaucher's disease. Lancet 339(8798):889–892
Peters S, Coyle P et al (1976) Differantiation of beta glucocerebrosidase form beta glucosidase in human tissues using sodium taurocholate. Arch Biochem Biophys 175:562–569
Richards B, Skoletsky J, Shuber AP, Balfour R, Stern RC, Dorkin HL, Parad RB, Witt D, Klinger KW (1993) Multiplex PCR amplification from the CFTR gene using DNA prepared from buccal brushes/swabs. Hum Mol Genet 2:159–163
Rozenberg R, Araujo FT et al (2006) High frequency of mutation G377S in Brazilian type 3 Gaucher disease patients. Braz J Med Biol Res 39(9):1171–1179
Schoonhoven A, Rudensky B et al (2007) Monitoring of Gaucher patients with a novel chitotriosidase assay. Clin Chim Acta 381(2):136–139
Vieira V (2000) Os Gadelhas no Mundo. http://www.gentree.org.br/artigos/gadelha.htm . Accessed 13 May 2009
Weinreb N, Barranger J et al (2007) Imiglucerase (Cerezyme) improves quality of life in patients with skeletal manifestations of Gaucher disease. Clin Genet 71(6):576–588
Acknowledgments
The authors would like to thank the team at Genzyme do Brasil, sponsor of the study. Also many thanks to Dr. Elisa Sobreira for scientific support, Prof. Antonio Toledo Jr. for assistance with the manuscript, and Dr. Erlane Marques Ribeiro for help with the study design. We are also in debt to João Márcio da Silva, head of the Municipal Department of Health, and to the staff of the Family Health Program in Tabuleiro do Norte for their cooperation. Last but not least, we are appreciative of the valuable support received from ACDG (Associação Cearense de Profissionais atuantes em Doenças Genéticas, Pacientes, Familiares e Voluntários).
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Appendices
Synopsis
Enzyme assay with DBS-FP was shown to be an effective initial GD-screening strategy for high-prevalence populations in developing regions when followed by measurement of GBA activity in leukocytes, but molecular analysis was necessary to confirm diagnosis (homozygous, heterozygous, and normals for GD).
Conflicts of Interest
Rigoberto Chaves and Tibelle Maurício received educational grants from Genzyme do Brasil to help develop the study. Genzyme do Brasil covered the travel expenses and training of Rômulo Maurício and sponsored the laboratory tests performed by Janice Coelho and Kristiane Michelin-Tirelli. No other conflicts of interest are reported.
Rights and permissions
Copyright information
© 2011 SSIEM and Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
Chaves, R.G. et al. (2011). Successful Screening for Gaucher Disease in a High-Prevalence Population in Tabuleiro do Norte (Northeastern Brazil): A Cross-Sectional Study. In: JIMD Reports - Case and Research Reports, 2011/1. JIMD Reports, vol 1. Springer, Berlin, Heidelberg. https://doi.org/10.1007/8904_2011_19
Download citation
DOI: https://doi.org/10.1007/8904_2011_19
Received:
Revised:
Accepted:
Published:
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-17707-1
Online ISBN: 978-3-642-17708-8
eBook Packages: MedicineMedicine (R0)